Drug Trial Radar · NCT05050149
Study Evaluating the Safety and Efficacy of PTX-022 (QTORIN Sirolimus) in the Treatment of Microcystic Lymphatic Malformations
Last checked: Nov 19, 2026Latest source record: Jan 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
12
Actual
Start
Jan 13, 2022
Primary completion
Nov 15, 2022
Study completion Dec 15, 2022
Sponsor
- Lead sponsor
- Palvella Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 20, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluates the safety and efficacy of PTX-022 (sirolimus) Topical Gel 3.9% w/w in the treatment of Microcystic Lymphatic Malformations. The participant will receive 3 months of PTX-022 treatment by the end of the study.
Conditions
- Microcystic Lymphatic Malformation
Interventions
PTX-022Drug
Safety and Efficacy of PTX-022 in the Treatment of Microcystic Lymphatic Malformations
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment-Emergent Adverse EventsTime frame: 4 months
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Arkansas Children's Hospital
Little Rock, Arkansas
Stanford University
Palo Alto, California
Minnesota Clinical Study Center
Fridley, Minnesota
Vascular Birthmark Institute
New York, New York
Cincinnati Children's Hospital
Cincinnati, Ohio
Oregon Health and Science University
Portland, Oregon
Children's Hospital of Pennsylvania (CHOP)
Philadelphia, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.